SVB Leerink Downgrades Moderna (MRNA) to Underperform

SVB Leerink analyst Mani Foroohar downgraded Moderna (NASDAQ: MRNA) from Market Perform to Underperform with a price target of $93.00 (from $111.00).

For an analyst ratings summary and ratings history on Moderna click here. For more ratings news on Moderna click here.

Shares of Moderna closed at $147.57 yesterday.

You May Also Be Interested In

• Wolfe Research Downgrades T-Mobile (TMUS) to Peerperform
• Freedom Broker Double Downgrades Mosaic (MOS) to Sell
• Rockwell Automation (ROK) PT Raised to $514 at Bernstein SocGen Group